Gland Pharma has over 30 years of experience manufacturing heparin APIs and formulations. Stringent analytical methods, including proton NMR and capillary electrophoresis as recommended by the FDA, are used to check for impurities in heparin sodium batches. A review of NMR data and testing batches from 2007 by capillary electrophoresis found none of Gland's heparin sodium batches exhibited peaks associated with OSCS contamination, confirming the absence of contamination. NMR spectra and electropherograms of Gland's heparin are provided for comparison with FDA's published data.
Gland Pharma has over 30 years of experience manufacturing heparin APIs and formulations. Stringent analytical methods, including proton NMR and capillary electrophoresis as recommended by the FDA, are used to check for impurities in heparin sodium batches. A review of NMR data and testing batches from 2007 by capillary electrophoresis found none of Gland's heparin sodium batches exhibited peaks associated with OSCS contamination, confirming the absence of contamination. NMR spectra and electropherograms of Gland's heparin are provided for comparison with FDA's published data.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Gland Pharma has over 30 years of experience manufacturing heparin APIs and formulations. Stringent analytical methods, including proton NMR and capillary electrophoresis as recommended by the FDA, are used to check for impurities in heparin sodium batches. A review of NMR data and testing batches from 2007 by capillary electrophoresis found none of Gland's heparin sodium batches exhibited peaks associated with OSCS contamination, confirming the absence of contamination. NMR spectra and electropherograms of Gland's heparin are provided for comparison with FDA's published data.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Gland Pharma has more than three decades of experience with heparin and has been manufacturing heparin and various low molecular weight heparins, both the active pharmaceutical ingredients (APIs) and their formulations and also marketing them in India and abroad. Stringent analytical methods and systems are in place to ensure the quality of the APIs and injections. Apart from the pharmacopoeial methods, in-house analytical methods are included to check the impurities related to heparin. Proton NMR analysis, similar to the one suggested by US FDA, is one of them and is carried out routinely for all the batches of heparin sodium (API) since 2002. Review of our NMR data of all the batches of heparin revealed that NONE of the heparin sodium APIs exhibited the peak at 2.15 + 0.02ppm assigned to the contaminant OSCS and thus proved the absence of contamination. Capillary electrophoresis (CE) is another test suggested by FDA to detect the impurity. Gland tested all its heparin batches received in the year 2007 by the capillary electrophoresis method recommended by US FDA and found that NONE of the batches showed the peak due to the contaminant (OSCS) which further confirms the absence of contamination. The NMR spectra and the electropherograms of Glands heparin sodium in comparison with those published by US FDA are enclosed herewith.
Confidential Gland Pharma Ltd, Hyderabad, India
Impurity evaluation of Heparin Sodium
NMR spectra of Glands Heparin sodium in comparison with FDAs published NMR spectra
Confidential Gland Pharma Ltd, Hyderabad, India
Impurity evaluation of Heparin Sodium
Confidential Gland Pharma Ltd, Hyderabad, India
Impurity evaluation of Heparin Sodium
CE Electropherogram of Glands Heparin sodium in comparison with FDAs published CE data
Confidential Gland Pharma Ltd, Hyderabad, India
Impurity evaluation of Heparin Sodium
Electropherogram of Glands Heparin sodium No extra peak detected - lot 1
Electropherogram of Glands Heparin sodium No extra peak detected - - lot 2
Analytical Method Development and Validation of Stability Indicating RP-HPLC Method For Estimation of Lercanidipine Hydrochloride and Enalapril Maleate in Combination